Advancing next-generation therapeutics for migraine and other headache disorders

Migraine causes significant disability and profoundly impacts quality of life. It’s the top cause of disability in people under the age of 50¹, the third leading cause of overall neurological disease burden (as measured by age-standardized disability-adjusted life years) and a leading cause of lost productivity and missed school/work². The disability caused by migraines is far broader than just headaches and comprises a range of debilitating symptoms, all of which can significantly impact a person’s ability to function.

Many migraine patients are underserved by the current standard of care – including CGRP inhibitors (calcitonin gene-related peptide) – and still experience significant disease burden in their everyday lives. CGRP inhibitors can be effective for acute and preventive treatment, but they rarely provide patients with complete control of their disease.